$PTI News
Last published 2y ago
- 2y agoPTIHarness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board ChairGlobeNewswireMs. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next
- 5y agoPTIProteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split RatioPR NewswireProteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of...
- 5y agoPTIYumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with ProteostasisGlobeNewswireLeading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis...
- 5y agoPTIProteostasis Therapeutics Reports Third Quarter 2020 Financial ResultsPR NewswireProteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company, today announced financial results for the third quarter...
- 6y agoHTGCOSHPLTROM+5Hercules Capital Reports Third Quarter 2020 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the third quarter ended September 30, 2020.
- 6y agoPTIPINCRallybio Appoints Helen M. Boudreau to Board of DirectorsBusiness WireNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that it has appointed Helen M. Boudreau, former Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, to its Board of Directors. Ms. Boudreau will also ...
- 6y agoPTISTOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Proteostasis Therapeutics, Inc. - PTIPR NewswireJuan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in ...
- 6y agoDCOMMXIMCGIXPTIMoore Kuehn Encourages MXIM, CGIX, PTI, and DCOM Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
- 6y agoPTIYumanity Therapeutics and Proteostasis Therapeutics Announce Merger AgreementPR NewswireYumanity Therapeutics and Proteostasis Therapeutics, Inc. (Nasdaq: PTI) today announced that the companies have entered into a definitive merger...
- 6y agoPTIProteostasis Therapeutics Reports Second Quarter 2020 Financial ResultsPR NewswireProteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 6y agoPTIProteostasis Therapeutics Announces Change to Virtual Format for 2020 Annual Meeting of StockholdersPR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 6y agoPTIProteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19PR NewswireProteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 6y agoPTIProteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdatePR NewswireProteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 6y agoPTIProteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual ConferencePR NewswireProteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 6y agoPTIProteostasis Therapeutics Announces Completion of Scientific Advice Meeting with the Dutch Medicines Evaluation BoardPR NewswireProteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 6y agoPTINVSBMYVasomune Therapeutics Appoints Meenu Chhabra to its Board of DirectorsBusiness WireTORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., an early stage therapeutic biopharmaceutical company developing a novel first-in-class medicine for the treatment of COVID-19/pathogen-induced ARDS, today announced the appointment of Meenu Chhabra to the Company’s Board of Directors. Ms. Chhabra is the President and Chief Executive Officer of Proteostasis Therapeutics, Inc. (NASDAQ:PTI).
- 6y agoPTIProteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate UpdatePR NewswireProteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 6y agoPTIProteostasis Therapeutics Announces New Publication on the Mechanism of Action of a Novel Class of CFTR Modulators Called Amplifiers in the Journal of Cystic FibrosisPR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 6y agoPTIProteostasis Therapeutics and CF Europe Announce Completion of Patient Enrollment for CHOICES, the First-Ever Personalized Medicine-Based Study in Cystic FibrosisPR NewswireProteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 6y agoPTIProteostasis Therapeutics Announces Keystone Symposia Presentation of Organoid Study from More than 300 Adult CF PatientsPR NewswireProteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 6y agoPTIProteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis PatientsPR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 6y agoCNSPAGIOPTILLY+1Why Pharmaceutical R&D Global Spending Could Exceed $200 Billion by 2024PR NewswireAccording to various industry and market publications, pharmaceutical companies spend, on average, 17% of revenues on R&D, making it one of the...
- 6y agoPTIProteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR ModulatorsPR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 6y agoPTIProteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare ConferencePR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 6y agoPTIProteostasis Therapeutics Regains Compliance with Nasdaq Listing StandardsPR NewswireProteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 7y agoPTIProteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdatePR NewswireProteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 7y agoPTIProteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic FibrosisPR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 7y agoPTIProteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis ConferencePR NewswireProteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 7y agoPTIProteostasis Therapeutics to Host Cystic Fibrosis Summit on Disparity in Access to CFTR Modulators Based on Geography Featuring Members of the Cystic Fibrosis Community and Thought LeadersPR NewswireProteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 7y agoPTIProteostasis Therapeutics to Present at the 2019 Cantor Global Healthcare ConferencePR NewswireProteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking ...
- 7y agoPTIProteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis ConferencePR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 7y agoPTIProteostasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate UpdatePR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 7y agoPTIProteostasis Therapeutics Initiates Dosing in Global Phase 2 Study in Cystic FibrosisPR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 7y agoPTIProteostasis Therapeutics Announces Management Changes and AppointmentsPR NewswireProteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of...
- 15y agoPTIiGATE Patni to Co-Host Webinar about ‘Making Cloud Economics Work for the Global Enterprise’Business WireFREMONT, Calif.--(BUSINESS WIRE)--iGATE Patni, the integrated technology and operations brand providing Business Outcomes-based solutions, today announced that it will co-host an educational webinar with Amazon Web Services, titled “Making Cloud Economics Work for the Global Enterprise,” on Tuesday, June 7, at 2 p.m. EDT.
- 15y agoPTIiGATE Patni to Co-Host Webinar about ‘Making Cloud Economics Work for the Global Enterprise’Business WireFREMONT, Calif.--(BUSINESS WIRE)--iGATE Patni, the integrated technology and operations brand providing Business Outcomes-based solutions, today announced that it will co-host an educational webinar with Amazon Web Services, titled “Making Cloud Economics Work for the Global Enterprise,” on Tuesday, June 7, at 2 p.m. EDT.